Paul Breckinridge “Breck” Jones WG83, a self-described serial entrepreneur, left a successful real estate business in Louisville, Kentucky, to start a specialty pharma firm back in 2001. Since then, US WorldMeds has developed drugs for those who face challenging medical conditions, like Parkinson’s, and its latest drug is no exception.
The medication, called Lucemyra, was approved and released in August to help fight the U.S. opioid epidemic; specifically, it’s the first (and only) non-opioid to treat and relieve withdrawal symptoms. Says Jones: “We are grateful for the urgency demonstrated by the FDA in rapidly reviewing and approving this important treatment.”
Read more from the Watchlist.
